GHRP-6 Price Comparison — Compare 8 Vendors
Price Comparison
Compare vendors · per 10mg
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| Core Peptides5.5/10 | $29.00 | $2.90 | Apr 16, 2026 | Buy → |
| SomaChems7/10 | $15.99 | $3.20 | May 14, 2026 | Buy → |
| CertaPeptides7.5/10 | $41.00 | $4.10 | Jun 27, 2026 | Buy → |
| Biotech Peptides6/10 | $21.00 | $4.20 | May 14, 2026 | Buy → |
| Polar Peptides5/10 | $43.19 | $4.32 | Apr 17, 2026 | Buy → |
| Evo Labs Research8/10 | $50.99 | $5.10 | Jun 22, 2026 | Buy → |
Research details
GHRP-6 — research data
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Overview
About GHRP-6
Mechanism of action
Hexapeptide ghrelin mimetic; binds GHS-R1a; stimulates GH and IGF-1; increases appetite significantly via hypothalamic ghrelin pathways; gastric motility enhancement.
Safety profile
Strong appetite increase (advantage or disadvantage), water retention, cortisol/prolactin elevation, fatigue, hypoglycemia risk if not eating. · Human studies exist; stronger hunger/cortisol response than GHRP-2; water retention; tolerable
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops GHRP-6 below your target.
Related pages
More on GHRP-6
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2), first characterized by Bowers et al. (Endocrinology 1984), acts as a synthetic agonist of the ghrelin/GHS-R1a receptor to potently stimulate pituitary GH release via both hypothalamic GHRH amplification and direct pituitary PI turnover — with maximal GH release requiring intact endogenous GHRH (Pandya et al., JCEM 1998).
- Beyond GH secretagogue activity, GHRP-6 exhibits potent cytoprotective and cardioprotective properties via CD36 and GHS-R1a receptor signaling: in an acute myocardial infarction model, GHRP-6 reduced infarct mass by 78% and decreased myocardial necrosis — effects now categorized as a distinct pharmacological class independent of GH secretion.